



Cornerstone
Medical
Education

AA[®]CME[®]
AMERICAN ACADEMY OF CME, INC.

An Expert Appraisal of the Latest Science and the Evolving Treatment Landscape in ATTR: Achieving Outcomes Synergy at the Cardiologist-Neurologist Interface



AA[®]CME[®]
AMERICAN ACADEMY OF CME, INC.

Presented by Cornerstone Medical Education, LLC.
This activity is supported through an independent educational
grant from AstraZeneca and Ionis Pharmaceuticals.

Bibliography & Suggested Reading

Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *J Neurol*. 2021;268(6):2109-2122.

Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *N Engl J Med*. 2018;379(1):11-21.

Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. *Nat Rev Neurol*. 2019;15(7):387-404.

Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. *Amyloid*. 2023;30(1):1-9.

Adams D, Wixner J, Polydefkis M, et al. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. *JAMA Neurol.* 2025;82(3):228-236.

Aimo A, Castiglione V, Rapezzi C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. *Nat Rev Cardiol.* 2022;19(10):655-667.

Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. *Amyloid.* 2022;29(3):143-155.

Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis.* 2013;8:31.

AstraZeneca Press Release. Eplontersen demonstrated sustained benefit in phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks. March 27, 2023. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2023/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial.html>. Accessed September 2025.

AstraZeneca Press Release. Eplontersen granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis. December 21, 2023. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis>. Accessed September 2025.

AstraZeneca Press Release. Eplontersen met co-primary and secondary endpoints in interim analysis of the NEURO-TTRansform phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). June 21, 2022. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2022/eplontersen-phase-iii-trial-met-co-primary-endpoints.html>. Accessed September 2025.

Aung N, Nicholls HL, Chahal CAA, et al. Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population. *JAMA Cardiol.* 2024;9(11):964-972.

Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *N Engl J Med.* 2018;379(1):22-31.

Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. *JAMA.* 2013;310(24):2658-2667.



Bhatt K, Delgado DH, Khella S, et al. Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program. *J Am Heart Assoc.* 2024;13(23):e033770.

BioSpace website. BridgeBio presents detailed positive results from phase 3 ATTRIBUTE-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023. August 27, 2023. Available at:

<https://www.biospace.com/article/releases/bridgebio-presents-detailed-positive-results-from-phase-3-attribute-cm-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-at-european-society-of-cardiology-congress-2023/>. Accessed September 2025.

Brannagan TH 3rd, Berk JL, Gillmore JD, et al. Liver-directed drugs for transthyretin-mediated amyloidosis. *J Peripher Nerv Syst.* 2022;27(4):228-237.

BridgeBio Press Release. BridgeBio pharma announces submission of new drug application to US FDA for acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). December 5, 2023. Available at: <https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-submission-new-drug-application-nda>. Accessed September 2025.

Brunjes DL, Castano A, Clemons A, et al. Transthyretin Cardiac Amyloidosis in Older Americans. *J Card Fail.* 2016;22(12):996-1003.

Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. *Amyloid.* 2022;29(4):213-219.

Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. *J Neurol Neurosurg Psychiatry.* 2022;93(6):668-678.

Castaño A, DeLuca A, Weinberg R, et al. Serial scanning with technetium pyrophosphate (^{99m}Tc-PYP) in advanced ATTR cardiac amyloidosis. *J Nucl Cardiol.* 2016;23(6):1355-1363.

Castaño A, Drachman BM, Judge D, et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. *Heart Fail Rev.* 2015;20(2):163-178.

Chandrashekar P, Alhuneafat L, Mannello M, et al. Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review. *Circ Genom Precis Med.* 2021;14(5):e003356.



Chiti F, Dobson CM. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. *Annu Rev Biochem.* 2017;86:27-68.

Cision PR Newswire. Ionis announces FDA acceptance of new drug application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy. March 7, 2023. Available at: <https://www.prnewswire.com/news-releases/ionis-announces-fda-acceptance-of-new-drug-application-for-eplontersen-for-the-treatment-of-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-301764027.html>. Accessed September 2025.

Cision PR Newswire. Ionis completes enrollment in landmark phase III CARDIO-TTRtransform study in patients with TTR-mediated amyloid cardiomyopathy. July 31, 2023. Available at: <https://www.prnewswire.com/news-releases/ionis-completes-enrollment-in-landmark-phase-3-cardio-ttransform-study-in-patients-with-ttr-mediated-amyloid-cardiomyopathy-301888878.html>. Accessed September 2025.

Coelho T, Ando Y, Benson MD, et al. Design and Rationale of the Global Phase 3 NEURO-TTRtransform Study of Antisense Oligonucleotide AKCEA-TTR-L_{Rx} (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. *Neurol Ther.* 2021;10(1):375-389.

Coelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. *JAMA.* 2023;330(15):1448-1458.

Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. *Curr Med Res Opin.* 2013;29(1):63-76.

Conceição I, González-Duarte A, Obici L, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. *J Peripher Nerv Syst.* 2016;21(1):5-9.

Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. *Eur J Heart Fail.* 2021;23(2):277-285.

Dispenzieri A, Coelho T, Conceição I, et al. Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. *Orphanet J Rare Dis.* 2022;17(1):236.

Drugs@FDA: FDA-Approved Drugs. Acoramidis. November 22, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf. Accessed September 2025.



Drugs@FDA: FDA-Approved Drugs. Eplontersen. April 18, 2025. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217388Orig1s004lbl.pdf. Accessed
September 2025.

Drugs@FDA: FDA-Approved Drugs. Patisiran. January 13, 2023. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210922s012lbl.pdf. Accessed
September 2025.

Drugs@FDA: FDA-Approved Drugs. Tafamidis. October 17, 2023. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211996s002,212161s002lbl.pdf.
Accessed September 2025.

Drugs@FDA: FDA-Approved Drugs. Vutrisiran. March 20, 2025. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215515s006lbl.pdf. Accessed
September 2025.

Ekpo E, Elmore J, Khendraki R. *Amyloid*. 2024;31(Suppl 1):S141-S142. Abstract #343. Poster available
at:
<https://www.morressier.com/o/event/652e68edc5482a001283848b/article/65f9bf8ae6f73964e1d4f23c>.
Accessed September 2025.

Elliott P, Drachman BM, Gottlieb SS, et al. Long-Term Survival With Tafamidis in Patients With
Transthyretin Amyloid Cardiomyopathy. *Circ Heart Fail*. 2022;15(1):e008193.

Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with
Cardiomyopathy. *N Engl J Med*. 2025;392(1):33-44.

Fontana M, Masi A, Garcia-Pavia P, et al. Study design of the CARDIO-TTRansform cardiac magnetic
resonance imaging substudy. *Eur Heart J*. 2024;45(supplement_1).

Fontana M, Solomon SD, Kachadourian J, et al. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran
for ATTR Cardiomyopathy. *N Engl J Med*. 2024;391(23):2231-2241.

Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a Real-World Cohort of Patients With
Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin
Amyloidosis Outcomes Survey (THAOS). *J Card Fail*. 2025;31(3):525-533.



Gentile L, Diemberger I, Plante-Bordeneuve V, et al. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS). *PLoS One*. 2024;19(1):e0292435.

Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. *BMC Fam Pract*. 2020;21(1):198.

Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. *J Am Coll Cardiol*. 2015;66(21):2451-2466.

Gertz MA, Mauermann ML, Grogan M, et al. Advances in the treatment of hereditary transthyretin amyloidosis: A review. *Brain Behav*. 2019;9(9):e01371.

Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. *N Engl J Med*. 2021;385(6):493-502.

Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. *N Engl J Med*. 2024;390(2):132-142.

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*. 2016;133(24):2404-2412.

González-Moreno J, Dispenzieri A, Grogan M, et al. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey. *Cardiol Ther*. Published online December 20, 2023.

Griffin JM, Grodin JL, Ruberg FL, et al. Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. *JACC Heart Fail*. 2025;13(5):685-694.

Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. *Circ Res*. 2021;128(10):1554-1575.

Grogan M, Scott CG, Kyle RA, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System [published correction appears in *J Am Coll Cardiol*. 2017 Jun 13;69(23):2882]. *J Am Coll Cardiol*. 2016;68(10):1014-1020.

Hawkins PN, Ando Y, Dispenzieri A, et al. Evolving landscape in the management of transthyretin amyloidosis. *Ann Med*. 2015;47(8):625-638.



Ionis PR Newswire Press Release. Eplontersen granted US FDA fast track designation for patients with transthyretin-mediated amyloid cardiomyopathy. February 8, 2024. Available at: <https://www.prnewswire.com/news-releases/eplontersen-granted-us-fda-fast-track-designation-for-patients-with-transthyretin-mediated-amyloid-cardiomyopathy-302056803.html>. Accessed September 2025.

Judge DP, Alexander KM, Cappelli F, et al. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. *J Am Coll Cardiol*. 2025;85(10):1003-1014.

Judge DP, Kristen AV, Grogan M, et al. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) [published correction appears in *Cardiovasc Drugs Ther*. 2020 Jun 16;:]. *Cardiovasc Drugs Ther*. 2020;34(3):357-370.

Kadakia KT, Kittleson MM, Krumholz HM. The Evolving Therapeutic Paradigm for Cardiac Amyloidosis. *J Am Coll Cardiol*. 2025;85(20):1907-1910.

Kaniper S, Lynch D, Owens SM, et al. Non-Cardiac Amyloidosis Findings Are Not Increased in African American Carriers of TTR V142I with Heart Failure and/or Arrhythmia. *J Pers Med*. 2024;14(3):271.

Karam C, Mauermann ML, Gonzalez-Duarte A, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts. *Muscle Nerve*. 2024;69(3):273-287.

Khella S, Bumma N, Gabriel A, et al. Genetic testing for hereditary ATTR amyloidosis: insights from the hATTR Compass Program. *Neurology*. 2020;94(15_supplement).

Khella S, et al. Low Transthyretin Level is Associated with Severe and Fatal Diseases: Insights from the UK Biobank Database. Presented at: 2025 Peripheral Nerve Society (PNS) Annual Meeting; May 17-20; Edinburgh, Scotland. P470.

Kittleson MM, Panjra GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023;81(18):1835-1878.

Kozlitina J, Garg S, Drazner MH, et al. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population. *J Card Fail*. 2022;28(3):403-414.



Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. *Blood*. 2012;120(16):3206-3213.

Lopes LR, Futema M, Akhtar MM, et al. Prevalence of *TTR* variants detected by whole-exome sequencing in hypertrophic cardiomyopathy. *Amyloid*. 2019;26(4):243-247.

Luigetti M, Quan D, Berk JL, et al. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study. *Neurol Ther*. 2024;13(3):625-639.

Masri A, Bhattacharya P, Medoff B, et al. A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy. *JACC CardioOncol*. 2025;7(3):282-293.

Masri A, Maurer MS, Claggett BL, et al. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. *J Card Fail*. 2024;30(8):973-980.

Maurer M, Cappelli F, Fontana M, et al. Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) : insights from ATTRIBUTE-CM and its open-label extension. *Eur Heart J*. 2024 ;45(supplement_1).

Maurer MS, Bokhari S, Damy T, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. *Circ Heart Fail*. 2019;12(9):e006075.

Maurer MS, et al. *N Engl J Med*. 2018;379(11):1007-1016

Maurer MS, Hanna M, Grogan M, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). *J Am Coll Cardiol*. 2016;68(2):161-172.

Maurer MS, Judge DP, Gillmore JD, et al. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. *J Am Coll Cardiol*. 2025;85(20):1911-1923.

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *N Engl J Med*. 2018;379(11):1007-1016.

Maurer MS. Primary results from APOLLO-B, a phase III study of patisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy. September 30, 2022. PDF Poster available at: https://capella.alnylam.com/wp-content/uploads/2022/09/Poster-341_APOLLO-B-Primary_Maurer_30Sept2022_v3.pdf. Accessed September 2025.



Murad A, Lasko M, Badri P, et al. A phase I, single ascending dose to evaluate ALN-TTRsc04, a next-generation RNA interference therapeutic, in healthy participants for potential treatment of transthyretin amyloidosis. *Circulation*. 2024;150(supplement_1). Abstract #4135443.

Naiki H, Sekijima Y, Ueda M, et al. Human amyloidosis, still intractable but becoming curable: The essential role of pathological diagnosis in the selection of type-specific therapeutics. *Pathol Int*. 2020;70(4):191-198.

Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. *Curr Opin Cardiol*. 2018;33(5):571-579.

Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR Epidemiology, Genetics, and Prognostic Factors. *Methodist DeBakey Cardiovasc J*. 2022;18(2):17-26.

Picken MM. The Pathology of Amyloidosis in Classification: A Review. *Acta Haematol*. 2020;143(4):322-334.

Quarta CC, Falk RH, Solomon SD. V122I transthyretin variant in elderly black Americans. *N Engl J Med*. 2015;372(18):1769.

Rao VN, Claggett BL, Khouri MG, et al. Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant. *Circ Heart Fail*. 2025;18(7):e013212.

Regan JA, Fontana M, Selvaraj S. Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection. *JAMA Cardiol*. 2024;9(11):957-959.

Regan JA, Khouri MG, Olabisi OA, et al. Should We Systematically Screen for the Amyloidogenic V142I Variant?. *J Card Fail*. 2025;31(1):136-139.

Rintell D, Heath D, Braga Mendendez F, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. *Orphanet J Rare Dis*. 2021;16(1):70.

Robbins J. *Clin Chem Lab Med*. 2002;40:1183-1190.

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019;73(22):2872-2891.

Saraiva MJ. Transthyretin amyloidosis: a tale of weak interactions. *FEBS Lett*. 2001;498(2-3):201-203.

Scirpa R, Cittadini E, Mazzocchi L, et al. Risk stratification in transthyretin-related cardiac amyloidosis. *Front Cardiovasc Med*. 2023;10:1151803.



Selvaraj S, Claggett B, Shah SH, et al. Cardiovascular Burden of the V142I Transthyretin Variant. *JAMA*. 2024;331(21):1824-1833.

Selvaraj S, Claggett BL, Quarta CC, et al. Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US. *JAMA Cardiol*. 2023;8(8):784-788.

Shetty NS, Gaonkar M, Patel N, et al. Determinants of transthyretin levels and their association with adverse clinical outcomes among UK Biobank participants. *Nat Commun*. 2024;15(1):6221.

Sinha A, Zheng Y, Nannini D, et al. Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study. *JAMA Cardiol*. 2021;6(6):718-722.

Sperry BW, Hanna M, Maurer MS, et al. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. *JAMA Cardiol*. 2023;8(3):275-280.

Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. *J Intern Med*. 1994;235(5):479-485.

Tomasoni D, Bonfioli GB, Aimo A, et al. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials. *Front Cardiovasc Med*. 2023;10:1154594.

Tschöpe C, Elsanhoury A, Kristen AV. Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. *J Clin Med*. 2025;14(13):4785.

Tschöpe C, Elsanhoury A. Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges. *J Clin Med*. 2022;11(8):2148.

U.S. National Library of Medicine. ClinicalTrials.gov. Available at: <https://classic.clinicaltrials.gov/>. Accessed September 2025.

UAB website. UAB study reveals link between transthyretin levels and heart disease risk. July 26, 2024. Available at: <https://www.uab.edu/news/research-innovation/uab-study-reveals-link-between-transthyretin-levels-and-heart-disease-risk>. Accessed September 2025.

Vera-Llonch M, Reddy SR, Chang E, et al. The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis. *Orphanet J Rare Dis*. 2021;16(1):25.

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. *Lancet*. 2016;387(10038):2641-2654.



Witteles RM, Garcia-Pavia P, Damy T, et al. Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. *J Am Coll Cardiol*. Published online April 30, 2025.

Wixner J, Berk JL, Adams D, et al. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. *Amyloid*. 2025;32(1):29-38.

Writing Committee, Kittleson MM, Ruberg FL, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in *J Am Coll Cardiol*. 2023 Mar 21;81(11):1135]. *J Am Coll Cardiol*. 2023;81(11):1076-1126.

Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. *JACC Basic Transl Sci*. 2019;4(3):438-448.